EU drug regulator finds link between AstraZeneca vaccine and blood clots
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- JPMorgan (JPM) Reports a Q1 Beat on Revenue and Profit Fueled by Release of $5.2 Billion Reserved for Bad Loans; Shares Slightly Down
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
FILE PHOTO: Medical workers prepare doses of Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp, Belgium March 18, 2021. REUTERS/Yves Herman/File Photo
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Reuters) - Europe's drug regulator on Wednesday found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all available evidence.
"One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin," the European Medicines Agency (EMA) said.
The findings come as a major hurdle in the global fight against the pandemic and a shift in the stance of the regulator, which had last week backed the vaccine and said there was no increased risk of blood clots in general from the shot.
It is also a blow to AstraZeneca, which was a frontrunner in the race for making an effective vaccine against COVID-19 ever since it began working with the University of Oxford.
The EMA's safety committee, which was assessing the vaccine, has requested for more studies and changes to the current ones to get more information.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Denmark to Drop Use of AstraZeneca (AZN) Vaccine From Program - Bloomberg
- Ford details new production cuts due to global chip shortage
- Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
Create E-mail Alert Related CategoriesFDA, General News, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!